(4-(tetrahydro-2H-pyran-4-yl)phenyl)boronic acid | 865360-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (4-(tetrahydro-2H-pyran-4-yl)phenyl)boronic acid
• 英文别名: 4-(4-Tetrahydropyranyl)phenylboronic acid；[4-(oxan-4-yl)phenyl]boronic acid
• CAS: 865360-62-9
• 化学式: C₁₁H₁₅BO₃
• mdl: MFCD24448963
• 分子量: 206.049
• InChiKey: MYUSWMGNVKBANV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.88
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-溴-3-氟苯基)环丙烷-1-羧酸 、 (4-(tetrahydro-2H-pyran-4-yl)phenyl)boronic acid 在 palladium diacetate 、 四丁基溴化铵 、 sodium carbonate 作用下， 反应 1.0h， 生成 1-[2-fluoro-4'-(tetrahydropyran-4-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid
  参考文献：
  名称：

  Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid_1-42 Secretion

  摘要：

  Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID), has been recently described to selectively inhibit beta-amyloid(1-42) (A beta 42) secretion, the most toxic component of the senile plaques present in the brain of Alzheimer patients. The use of this NSAID in Alzheimer's disease (AD) is hampered by a significant gastrointestinal toxicity associated with cyclooxygenase (COX) inhibition. New flurbiprofen analogues were synthesized, with the aim of increasing A beta 42 inhibitory potency while removing anti-COX activity. In vitro ADME developability parameters were taken into account in order to identify optimized compounds at an early stage of the project. Appropriate substitution patterns at the alpha position of flurbiprofen allowed for the complete removal of anti-COX activity, while modifications at the terminal phenyl ring resulted in increased inhibitory potency on A beta 42 secretion. In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system. Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma A beta 42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD.

  DOI：

  10.1021/jm0502541

文献信息

• METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20160333021A1

  公开（公告）日：2016-11-17

  The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

  本发明涉及式(I)的化合物，这些化合物是金属β-内酰胺酶抑制剂，以及这些化合物的合成和与β-内酰胺类抗生素一起用于克服耐药性的用途。
• [EN] METALLO-BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLO-BÊTA-LACTAMASES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015112441A1

  公开（公告）日：2015-07-30

  The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

  本发明涉及式(I)的化合物，这些化合物是金属β-内酰胺酶抑制剂，以及这些化合物的合成和与β-内酰胺类抗生素一起用于克服耐药性的用途。
• [EN] C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER<br/>[FR] MODULATEURS DE TRADUCTION D'ARNM C-MYC ET LEURS UTILISATIONS DANS LE TRAITEMENT DU CANCER
  申请人：ANIMA BIOTECH INC

  公开号：WO2022150316A1

  公开（公告）日：2022-07-14

  The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.

  本发明涉及一种新型c-MYC mRNA翻译调节剂，其组成物和制备方法，以及在癌症治疗中的应用。
• Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers
  作者：Hong Jia、Wei Deng、Baoyu Hao、Min Cai、Dong Guo、Yu Cai、Xiaoming Dai、Zhipeng Wu、Weigang He、Jian Wang、Guanglin Wang、Sumei Xia、Na Li、Weiguo Su、Guangxiu Dai

  DOI：10.1021/acsmedchemlett.3c00553

  日期：2024.5.9

  that led to the discovery of the clinical-staged Syk inhibitor sovleplenib (41) via a structure–activity relationship investigation and pharmacokinetics (PK) optimization of a pyrido[3,4-b]pyrazine scaffold. Sovleplenib is a potent and selective Syk inhibitor with favorable preclinical PK profiles and robust anti-inflammation efficacy in a preclinical collagen-induced arthritis model. Sovleplenib is now

  在此，我们描述了通过吡啶并[3,4- b ]吡嗪支架的结构-活性关系研究和药代动力学（PK）优化发现临床阶段的Syk抑制剂sovleplenib（ 41 ）的药物化学工作。 Sovleplenib 是一种有效的选择性 Syk 抑制剂，在临床前胶原诱导的关节炎模型中具有良好的临床前 PK 曲线和强大的抗炎功效。 Sovleplenib 目前正在开发用于治疗自身免疫性疾病，例如免疫性血小板减少性紫癜和温抗体溶血性贫血以及血液恶性肿瘤。